Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.4400
+0.2250 (104.65%)
At close: Sep 2, 2025, 4:00 PM
0.3650
-0.0750 (-17.05%)
After-hours: Sep 2, 2025, 7:59 PM EDT

Company Description

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States.

Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis.

The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.

In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma.

Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies.

The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.

Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics, Inc.
Carisma Therapeutics logo
CountryUnited States
Founded2016
IndustryBiotechnology
SectorHealthcare
Employees46
CEOSteven Kelly

Contact Details

Address:
3675 Market Street, Suite 401
Philadelphia, Pennsylvania 19104
United States
Phone267 491 6422
Websitecarismatx.com

Stock Details

Ticker SymbolCARM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001485003
CUSIP Number14216R101
ISIN NumberUS14216R1014
Employer ID26-2025616
SIC Code2834

Key Executives

NamePosition
Steven KellyPresident, Chief Executive Officer and Director
Michael Klichinsky Ph.D., Pharm.D., PharmDCo-Founder and Chief Scientific Officer
Dr. Saar Gill M.D., Ph.D.Co-Founder and Chairman of Scientific Advisory Board
Natalie McAndrewVice President of Finance

Latest SEC Filings

DateTypeTitle
Sep 2, 2025SCHEDULE 13D/AFiling
Aug 29, 2025SCHEDULE 13D/AFiling
Aug 29, 2025S-4/AFiling
Aug 29, 2025425Filing
Aug 29, 20258-KCurrent Report
Aug 21, 2025SCHEDULE 13D/AFiling
Aug 8, 2025425Filing
Aug 8, 20258-KCurrent Report
Aug 7, 202510-QQuarterly Report
Jul 31, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material